StockData
EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

EXOZYMES INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$4.00−0.09 (-2.20%)

Close on Oct 19, 2026

Market cap
$34.64M
P/E (TTM)
–
Dividend yield
–

SEC filings

32 of Exozymes's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KOct 9, 2026Oct 9, 2026SEC EDGAR
Proxy statementDEF 14ANov 13, 2026Sep 28, 2026SEC EDGAR
Current report8-KSep 17, 2026Sep 18, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 13, 2026SEC EDGAR
Current report8-KJun 30, 2026Jul 1, 2026SEC EDGAR
Current report8-KJun 25, 2026Jun 26, 2026SEC EDGAR
Current report8-KJun 17, 2026Jun 17, 2026SEC EDGAR
Current report8-KJun 5, 2026Jun 8, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 14, 2026SEC EDGAR
Current report8-KMay 7, 2026May 7, 2026SEC EDGAR
Current report8-KApr 10, 2026Apr 10, 2026SEC EDGAR
Current report8-KMar 30, 2026Mar 31, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 30, 2026SEC EDGAR
Current report8-KJan 29, 2026Feb 5, 2026SEC EDGAR
Current report8-KDec 11, 2025Dec 12, 2025SEC EDGAR
Current report8-KNov 13, 2025Nov 13, 2025SEC EDGAR
Quarterly report10-QSep 30, 2025Nov 13, 2025SEC EDGAR
Current report8-KSep 30, 2025Oct 3, 2025SEC EDGAR
Quarterly report10-QJun 30, 2025Aug 12, 2025SEC EDGAR
Current report8-KJul 25, 2025Jul 28, 2025SEC EDGAR
Current report8-KJul 7, 2025Jul 8, 2025SEC EDGAR
Current report8-KJun 26, 2025Jun 26, 2025SEC EDGAR
Current report8-KJun 17, 2025Jun 20, 2025SEC EDGAR
Proxy statementDEF 14AJul 25, 2025Jun 20, 2025SEC EDGAR
Quarterly report10-QMar 31, 2025May 12, 2025SEC EDGAR
Current report8-KApr 2, 2025Apr 2, 2025SEC EDGAR
Current report8-KApr 2, 2025Apr 2, 2025SEC EDGAR
Annual report10-KDec 31, 2024Mar 31, 2025SEC EDGAR
Current report8-KFeb 17, 2025Feb 21, 2025SEC EDGAR
Current report8-KFeb 10, 2025Feb 11, 2025SEC EDGAR
Current report8-KNov 14, 2024Nov 18, 2024SEC EDGAR
Quarterly report10-QSep 30, 2024Nov 12, 2024SEC EDGAR